Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
NCT07212075 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1809
Last updated 2025-12-04
Summary
Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health.
Belonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups.
Over 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person.
The objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions.
To achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews.
The complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.
Conditions
- Diabetes (DM)
- Diabete Mellitus
- Diabete Type 1
- Diabete Type 2
- Diabetes Distress
- Diabetes Complications
- Depression - Major Depressive Disorder
- Depression Anxiety Disorder
- Depression Bipolar
- Depression Disorders
- Anxiety Disorder (Panic Disorder or GAD)
- Anxiety Disorder NOS
- Eating Disorder Binge
- Anorexia Nervosa
- Bulimia Nervosa
- Eating Disorder Not Otherwise Specified
- Depressed Mood
- Anxiety Symptoms
- Disordered Eating Behaviors
- Fear of Hypoglycemia
Sponsors & Collaborators
-
Forschungsinstitut der Diabetes Akademie Mergentheim
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-01
- Primary Completion
- 2027-08-31
- Completion
- 2027-12-31
Countries
- Germany
Study Locations
More Related Trials
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
NCT05193578 ·Status: COMPLETED ·Phase: PHASE2
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Antipsychotics and Risk of Hyperglycemic Emergencies
NCT02582736 ·Status: COMPLETED
-
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
NCT02069379 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
NCT03943537 ·Status: COMPLETED ·Phase: PHASE2
-
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
NCT05492305 ·Status: UNKNOWN
-
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
NCT04892199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00182494 ·Status: UNKNOWN ·Phase: PHASE4
-
Psychosis and Type 2 Diabetes Study (PODS)
NCT05496907 ·Status: UNKNOWN ·Phase: NA
-
Steroid and Behaviour Changes Under Metformin
NCT04930471 ·Status: UNKNOWN
-
Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients
NCT02644577 ·Status: COMPLETED ·Phase: PHASE4
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
NCT02423824 ·Status: COMPLETED ·Phase: PHASE3
-
Metabolic Syndrome in Patients With First-episode Schizophrenia
NCT00957294 ·Status: COMPLETED
-
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
NCT03271866 ·Status: UNKNOWN ·Phase: NA
-
Glycemic Index/ Load and Mental Disorders
NCT02362113 ·Status: UNKNOWN
-
Heart Rate Variability in Response to Metformin Challenge
NCT02500628 ·Status: COMPLETED ·Phase: PHASE2
-
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
NCT01845259 ·Status: UNKNOWN ·Phase: PHASE2
-
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
NCT02515773 ·Status: COMPLETED ·Phase: PHASE4
-
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
NCT00895921 ·Status: COMPLETED ·Phase: PHASE4
-
Pioglitazone in Patients With Mood Disorders
NCT01559857 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142 ·Status: RECRUITING ·Phase: PHASE3
-
The PsychOsis and Diabetes Service Model (PODS) Population Profile Study.
NCT05456984 ·Status: COMPLETED
-
Antipsychotic Medicine and Metabolic Syndrome
NCT00627757 ·Status: UNKNOWN